[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aptose Biosciences Inc (APS.TO)

Aptose Biosciences Inc (APS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aptose Biosciences Inc 66 Wellington Street West Suite 5300, TD Bank Tower Box 48 Toronto ON M5K 1E6 CAN

https://www.aptose.com P: 647-479-9828

Sector:

Medical

INDUSTRY GROUPING:

TSX Biotechnology

Description:

Aptose Biosciences Inc is a clinical-stage biotechnology company. Its compound tuspetinib is a convenient once daily oral agent that potently targets SYK, mutated and wild-type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases, while avoiding many typical toxicity concerns observed with other agents. The ongoing TUSCANY triplet Phase 1/2 study is designed to test various doses and schedules of TUS in combination with standard dosing of azacitidine and venetoclax in newly diagnosed patients with AML who are ineligible to receive induction chemotherapy. The group has reported data from the first three dose cohorts that demonstrated safety, CRs, and minimal residual disease (MRD) negativity across patients with diverse mutations.

Key Statistics

Overview:

Market Capitalization, $K 6,126
Shares Outstanding, K 2,552
% of Institutional Shareholders 0.02%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -25,468 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -7,759 K

Growth:

1-Year Return 101.68%
3-Year Return -98.67%
5-Year Return -99.87%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings -3.07 on 05/08/25
Next Earnings Date 08/12/26 [--]
Earnings Per Share ttm -10.41
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 02/26/25

APS.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -252.92%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book N/A
Book Value/Share -15.11
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.